Since Nov. 1, the following drugmakers have announced or completed acquisitions:
Note: This is not an exhaustive list. Deals were reported by Becker's Hospital Review and are presented in the order in which they were reported.
- Astellas Pharma to acquire Audentes Therapeutics in $3B deal
Astellas Pharma, a Tokyo, Japan-based drugmaker, plans to acquire San Francisco-based Audentes Therapeutics for about $3 billion. - Novartis pays $9.7B to acquire Medicines Co.
Novartis has acquired Parsipanny, N.J.-based drugmaker Medicines Co. for $9.7 billion. - Alkermes to acquire Rodin Therapeutics
Alkermes will acquire Boston-based drugmaker Rodin Therapeutics for $100 million to expand its portfolio of drugs to treat neurodegenerative disorders. - FTC clears Bristol-Myers takeover of Celgene
The Federal Trade Commission cleared the way for Bristol-Myers Squibb to complete its acquisition of Celgene for $74 billion, one of the largest deals in pharmaceutical history. - Roche to buy small Massachusetts drugmaker for $390M
Roche will pay $390 million to purchase a small Lexington, Mass.-based drugmaker, Promedior. - Amgen invests $2.7B in Chinese drugmaker
Amgen is investing $2.7 billion in a Chinese drugmaker, BeiGene, giving it a 20.5 percent stake in the company.
More articles on pharmacy:
Top 5 pharmacy stories in November
Juno Therapeutics co-founder starting new drug company
Parents in Europe crowdsource $2.7M to buy world's most expensive drug for their toddler